跳至主要内容
临床试验/JPRN-jRCT2071210038
JPRN-jRCT2071210038招募中2 期

Prevention of aggravation of moderate pneumonia caused by COVID - 19 using adrenomedullin - Investigator initiated phase 2a trial - AM-P2-COVID2

Kita Toshihiro0 个研究点目标入组 60 人开始时间: 2021年6月24日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 75age old(—)
性别
All

入选标准

  • Hospitalized patients with moderate COVID-19 pneumonia and within 10 days after onset

排除标准

  • patients with severe COVID-19 pneumonia
  • patients with liver dysfunction (AST and/or ALT > 5 times of reference values)
  • patients with renal dysfunction (serum creatinine > 2.0 mg/dl)
  • patients with severe ECG abnormalities and/or cardiac diseases
  • patients with malignancy or history of malignancy
  • patients who are expected to transfer to other hospital within 72 hours
  • pregnant or lactating women

研究者

发起方
Kita Toshihiro

相似试验